iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Holdings is well positioned to benefit from its dominant ~72% share of the sizable U.S. LTCM market, where strong clinical data and its algorithm, sensor, and back-office capabilities support a durable moat. The company also has a meaningful near-to-medium-term growth opportunity in MCT, with ~15% share today, potential FDA approval for Zio MCT in 1H: 27E, and the VitalConnect acquisition, which could help open the broader market and add substantial incremental revenue. Beyond core share gains, the business appears to be moving toward profitability, with gross margin above 70%, broad reimbursement coverage, and expanding upstream demand from PCPs and asymptomatic patients.

iRhythm Holdings is viewed negatively because its growth narrative appears fragile: the asymptomatic opportunity is opaque and may be overstated, while the MCT segment has seen launch pushouts and faces potential cannibalization from VitalConnect. Regulatory risk is also elevated, with a DOJ civil investigative demand on Zio AT reimbursement claims and an FDA warning letter in 2023, plus further inspection issues in 2024 that could ultimately lead to harsher outcomes than expected. On top of that, reimbursement pressure remains a structural headwind, with CMS accounting for about 25% of volumes, FY24 reimbursement rates declining across products, and annual rate changes that could compress ASP and utilization.